In partnership with the University of Texas System, a technology transfer was arranged which created Ampholife Technologies, Inc. (ATI). Ampholife Technologies, Inc. is a company formed in late 1988 to commercialize technology developed at the University of Texas-Houston for synthesizing high resolution carrier ampholytes and instrumentation for large-scale purification of biological materials. This was initially a technology transfer venture between the University of Texas System and Surgimedics, Inc. which is Texas' largest manufacturer and marketer of medical and biomedical products. As a result of an agreement between the University of Texas System and Surgimedics, Inc., Dr. Rodkey was appointed CEO and President of Ampholife Technologies. A stock transfer was negotiated which made Dr. Rodkey the majority stockholder of ATI. Ampholife Technologies, Inc. currently manufactures the ATIsolator, a high-volume protein purification instrument that utilizes a fluid-phase isoelectric focusing format for high-resolution preparative purification of biomolecules and holds the intellectual property rights to a series of ampholyte compounds which are used in the ATIsolator for pH gradient formation during the isoelectric focusing and can be used for preparative electrophoresis of viable cells and as buffers in solid-phase analysis of the Rh antigens of red blood cells. Ampholife Technologies, Inc. is now 76% owned by L. Scott Rodkey, with the University of Texas System owning 20% and G. David Huff owning 4%.
Ampholife Technologies, Inc. is currently seeking active partnerships with companies interested in further development of preparative-scale IEF for use in downstream purification of genetically engineered biologicals/pharmaceuticals. Additionally, we are interested in licensing our patented and proprietary chemistries for ampholyte and zwitterionic buffers. These chemistries provide inexpensive means for production of high-resolution ampholytes for use in IEF, 2-D electrophoresis and provide molecular mixtures useful for combinatorial chemistry applications. Recent studies supported by an NIH Advanced Technology grant culminated in the development of ampholyte mixtures that create pH gradients up to pH 12.
Further information on these technologies can be obtained from Dr. Rodkey at 979-690-5380 or by Email from scottrodkey@yahoo.com or from Luetta Allen at 713-500-3390 (office), or email Luetta.Allen@uth.tmc.edu
A list and description of the ATI patent portfolio can be found by clicking HERE.
Home
to the Pathology Department